← Back to headlines
Wedbush Maintains Bullish Stance on Nuvation Bio (NUVB) Following Safusidenib Rights Expansion
Wedbush analysts are bullish on Nuvation Bio after the company expanded its rights for the drug Safusidenib, signaling positive developments for the biotech firm.
12 Apr, 21:54 — 12 Apr, 21:54
Sources
Showing 1 of 1 sources
Related Stories
Oil Jumps Above $100 After US-Iran Talks Fail
just now
Philippine Tax Bureau Orders Probe of Vice President Sara Duterte and Husband
just now
Witness Testifies Suspects Confessed to $6.23M Fraud in Emefiele Trial
just now
Nigeria's Foreign Currency Taxes Surge to N6.33 Trillion Amid Naira Volatility
just now